The Utility and Limitations of CRP, ESR and DAS28-CRP in Appraising Disease Activity in Rheumatoid Arthritis
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Introduction Identifying and quantifying inflammatory disease activity in rheumatoid arthritis remains a challenge. Many studies have suggested that a large proportion of patients may have active inflammation, but normal inflammatory markers. Although various disease activity scores have been validated, most rely to large degree on biomarkers such as CRP and ESR. In this study, we examine the utility and limitations of these biomarkers, as well as the DAS28-CRP in appraising disease activity in RA. Methods 223 consecutive rheumatoid arthritis reporting knee arthralgia underwent synovial sampling of the affected knee via needle arthroscopy. The synovium was examined by microscopy with H+E staining as well as immunohistochemistry, and related to the ESR, CRP and DAS28-CRP on samples taken immediately before arthroscopy. Results Although a statistically significant positive correlation was observed between CRP and the level of inflammation in the biopsy retrieved (n=197, rho=0.43, CI 0.30 to 0.54, p<0.0001), there was histological evidence of inflammation in the synovium in 49.4% of the patients who had a normal CRP. A positive correlation was also observed between ESR and the level of inflammation in the biopsy retrieved (n=188, rho=0.29, CI 0.15 to 0.42 p<0.0001). A statistically significant but weak positive correlation was observed between the DAS28-CRP and synovial inflammation (n=189, rho=0.23, CI 0.09 to 0.37, p=0.0011). Only the CD19 infiltrate in the synovium correlated with serum CRP (n=70, rho=0.32, CI 0.08 to 0.52, p=0.0068). Conclusion CRP has a moderately strong relationship with disease activity, but there are significant pitfalls in the use of this biomarker in RA, and therefore a need interpret CRP results judiciously. The results of this study underline the heterogeneity of RA, and the need to develop improved panels of biomarkers, to better stratify RA, and to identify the cohort for whom inflammatory activity cannot be measured accurately with CRP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevoo, M. L. L., Van'T Hof, M. A., Kuper, H. H., Van Leeuwen, M. A., Van De Putte, L. B. A., & Van Riel, P. L. C. M. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380107 · Cited by 6,243
The Pathogenesis of Rheumatoid Arthritis
McInnes, I. B., & Schett, G. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1004965 · Cited by 5,514 · cited 1×
“Rheumatoid arthritis (RA) is a chronic, progressive autoimmune disorder characterized by synovial proliferation and degradation of articular cartilage and bone (1).”
BackgroundAletaha, D., Neogi, T., Silman, A. J., Funovits, J., Felson, D. T., Bingham, C. O., Birnbaum, N. S., Burmester, G. R., Bykerk, V. P., Cohen, M. D., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.138461 · Cited by 4,941
Treating rheumatoid arthritis to target: recommendations of an international task force
Smolen, J. S., Aletaha, D., Bijlsma, J. W. J., Breedveld, F. C., Boumpas, D., Burmester, G., Combe, B., Cutolo, M., de Wit, M., Dougados, M., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.123919 · Cited by 2,100
Wells, G., Becker, J.-C., Teng, J., Dougados, M., Schiff, M., Smolen, J., Aletaha, D., & van Riel, P. L. C. M. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.084459 · Cited by 878
Brown, A. K., Conaghan, P. G., Karim, Z., Quinn, M. A., Ikeda, K., Peterfy, C. G., Hensor, E., Wakefield, R. J., O'Connor, P. J., & Emery, P. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23945 · Cited by 785
Annals of the Rheumatic Diseases
(2024) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis · Cited by 712
Charles, P. J., Elliott, M. J., Davis, D., Potter, A. R., Kalden, J. R., Antoni, C., Breedveld, F. C., Js, S., Eberl, G., DeWoody, K. L., et al. (1999) · PubMed · Cited by 531
Charles, P., Elliott, M. J., Davis, D., Potter, A., Kalden, J. R., Antoni, C., Breedveld, F. C., Smolen, J. S., Eberl, G., deWoody, K., et al. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.3.1521 · Cited by 436 · cited 1×
“It is known, for example, that secretion of CRP is largely IL-6 and TNFα dependant, and novel therapies such as tocilizumab (23), tumor necrosis factor α inhibition (24) and indeed, tofacitinib, interrupt this pathway.”
Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission
Molenaar, E. T. H., Voskuyl, A. E., Dinant, H. J., Bezemer, P. D., Boers, M., & Dijkmans, B. A. C. (2004) · Arthritis & Rheumatism · doi:10.1002/art.11481 · Cited by 384 · cited 1×
“However, there is evidence that even in patients with sustained remission, progression of the disease in the form of the development of new erosions occurs in up to 33% of patients (29, 30).”
Background
Cited by
C-reactive protein and implications in rheumatoid arthritis and associated comorbidities
Pope, J. E., & Choy, E. H. (2021) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2020.11.005 · Cited by 320
Metadata
- Authors
- Orr, C. K., Najm, A., Young, F., McGarry, T., Biniecka, M., Fearon, U., & Veale, D. J.
- Venue
- Frontiers in Medicine
- Publisher
- Frontiers Media SA
- Published
- 2018-08-03
- Volume
- 5
- Pages
- 185-185
- ISSN
- 2296-858X (ISSN-L)
- OpenAlex
- W2805636409
- Cited by
- 170
- References
- 28
- FWCI
- 7.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.